Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome

References

• Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in PCOS. Obstet Gynecol 1997;90:392–5
   Google Scholar
• Dunaif A. Insulin resistance and ovarian hyper-androgenism. Endocrinologist 1992;2:248–60
   Google Scholar
• Acbay O, Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996;65:946–9
   PubMed Web of Science ®Google Scholar
• Barbieri RL, Smith S, Rayan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988;50:197–212
   PubMed Web of Science ®Google Scholar
• Conn 11, Jacobs HS. Managing hirsutism in gynaecological practice. Br J Obstet Gynaecol 1998; 105:687–96
   PubMedGoogle Scholar
• Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in PCOS? Am J Obstet Gynecol 1992;167:1807–12
   PubMed Web of Science ®Google Scholar
• Hoffman D, Klove K, Lobo R. The prevalence and significance of elevated dehydroepiandrosterone sulfate level in anovulatory women. Fertil Steril 1984;42:76–81
   Google Scholar
• Kolodziejczyk B, Duleba AJ, Spaczynski R, et al. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149–54
   PubMed Web of Science ®Google Scholar
• Lanzone A, Fulghesu AM, Guido M, et al. Differ-ential androgen response to adrenocorticotropic hormone stimulation in PCOS: relationship with insulin secretion. Fertil Steril 1992;58:296–30
   PubMed Web of Science ®Google Scholar
• Crave JC, Finbel S, Lejeune H, et al. Effect of diet and metformin administration on SHBG, andro-gen, and insulin in hirsutism and obese women. J Clin Endocrinol Metab 1995;80:2057–62
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Maggs DG, Spollet GR, et al. Efficacy and metabolic effects of metformin and troglita-zone in type two diabetes mellitus. N Engl J Med 1998;338:867–72
   PubMed Web of Science ®Google Scholar
• Smith S, Ravnikar VA, Barbieri RL. Androgen and insulin response to an oral glucose challenge in hyperandro genic women. Fertil Steril 1987;48:72–7
   Google Scholar
• Schriock ED, Buffington CK, Hubert GD. Diver-gent correlation of circulating dehydroepiandro-stenedione sulfate and testosterone with insulin level and insulin receptor binding. J Clin Endocrinol Metab 1988;66:1329–31
   Google Scholar
• Diamond MP, Grainger D, Laudaro AJ. Effect of acute physiological elevation of insulin on circulat-ing androgen levels in normal women. J Clin Endocrinol Metab 1991;72:883–7
   Google Scholar
• Nestler JE, Usiskin KS, Brlascini CO, et al. Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. J Clin Endocrinol Metab 1989;69: 1040–6
   PubMed Web of Science ®Google Scholar
• Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with polycystic ovary syndrome. J Clin Invest 1989;83:23–9
   PubMed Web of Science ®Google Scholar
• Nestler JE, Clore JN, Strauss JF III, et al. The effect ofhyperinsulinemia on serum testosterone, proges-terone, dehydroepiandrosterone sulfate and cortisol levels in normal women and in women with hyperandrogenism, insulin resistance and acanthosis nigricans. J Clin Endocrinol Metab 1987; 64:180–4
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Evans WS, et al. Effect of metformin on spontaneous and clomiphene-induced ovulation in the PCOS. N Engl J Med 1998;338:1876–80
   PubMed Web of Science ®Google Scholar
• Nestler JE, Beer NA, Jakubowicz DJ, et al. Effect of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in non-diabetic men. J Clin Endocrinol Metab 1994;78: 549–54
   PubMed Web of Science ®Google Scholar
• Ferrinan D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–9
   PubMed Web of Science ®Google Scholar
• Buyalos RP, Pekonen F, Halme JK, et al. The relationship between circulating androgens, obesity, hyperinsulinemia and serum insulin-like growth factor binding protein 1 in polycystic ovary syndrome. Am J Obstet Gynecol 1995;172:932–5
   PubMed Web of Science ®Google Scholar
• San Roman GA, Magoffin DA. Insulin-like growth factor binding proteins in ovarian follicles from women with polycystic ovarian disease: cellular source and levels in follicular fluid. J Clin Endocrinol Metab 1992;75:1010–14
   PubMed Web of Science ®Google Scholar
• Roth GS, Ingram DK, Lane M. Caloric restriction in primates and relevance to humans. Ann NY Acad Sci 2001;928:305–15
   PubMed Web of Science ®Google Scholar
• Morin Papunen LC, Koivunen RM, Rukonen A, et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69:691–6
   PubMed Web of Science ®Google Scholar
• Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and preg-nancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril1987;48:72–7
   PubMedGoogle Scholar
• Kocak M, Caliskan E, Simsir C, et al. Metformin therapy improves ovulatory rates, cervical scores and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002;77:101–6
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ. Decrease in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;29:617–23
   Google Scholar
• Dinmanti-Kkadarakis E, Kouli C, Tsianateli T, et al. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in PCOS. Eur J Endocrinol 1998;138:269–74
   Google Scholar